Ironshore Pharmaceuticals Inc. is a pharmaceutical company whose mission is to commercialize innovative, patient-centric treatment options to improve the lives of patients and caregivers.
Based in North Carolina, Ironshore Pharmaceuticals Inc. is responsible for the sales, marketing and distribution of pharmaceutical products within the US. Ironshore Pharmaceuticals & Development, Inc., based in Grand Cayman, develops novel therapeutics by leveraging its proprietary drug-delivery technology, DELEXIS®. Ironshore Pharmaceuticals Inc. and Ironshore Pharmaceuticals & Development, Inc. are both wholly owned subsidiaries of Highland Therapeutics, Inc. based in Toronto.
DELEXIS - Proprietary Drug Delivery Platform
Ironshore Pharmaceuticals & Development, Inc. has developed a novel oral, once-daily, drug delivery technology. DELEXIS has delayed-release properties that limit the release of the medication overnight and extended-release properties that control the release of the medication throughout the following day.
› Learn More About DELEXIS
Our Approach
Our lead products are targeted at helping ADHD patients and their families by leveraging proprietary technologies to address a significant unmet medical need – inadequate control of symptoms of ADHD during the morning routine.
Early Morning Functioning
A majority of surveyed families report ADHD symptoms as ‘severe’ or ‘moderate-to-severe’ during the morning routine – the period immediately upon waking until the patient leaves for work or school. This period is often the busiest and most chaotic for families.
Controlled Release
Ironshore has developed a proprietary, oral controlled-release technology for evening dosing of medication with delayed and extended release characteristics that is designed to provide for next-day therapeutic activity beginning in the early morning and lasting throughout the day.